Business Wire (Mon, 9:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,533 people get BAX articles and Market Currents by email alert.
Get email alerts on BAX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
Baxter International Inc. - Special CallTue, May 7
-
Business Wire (May 7, 2013)
-
Business Wire (May 6, 2013)
-
-
Business Wire (Apr 25, 2013)
-
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 24, 2013)
-
-
Business Wire (Apr 18, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
Why We Like Baxter's DividendValuentum • Thu, Oct 25, 2012 -
-
-
-
Baxter Still Defensive, But Is Now The Time For Offense?Stephen Simpson • Tue, May 15, 2012 -
Baxter Earnings PreviewZacks Investment Research • Tue, Apr 17, 2012 -
-
Baxter's A Buy For Growth, Cash Flow, And Rising DividendsIngrid Hendershot • Tue, Mar 13, 2012 -
-
-
-
-
Baxter International Inc. - Special CallTue, May 7
-
Baxter International Q2 2010 Earnings Call TranscriptThu, Jul 22, 2010
-
Baxter International Inc. Q1 2010 Earnings Call TranscriptThu, Apr 22, 2010
-
Baxter International Inc. Q4 2009 Earnings Call TranscriptThu, Jan 28, 2010
-
Baxter International Inc. Q3 2009 Earnings Call TranscriptThu, Oct 15, 2009
-
Baxter International Inc. Q2 2009 Earnings Call TranscriptThu, Jul 16, 2009
-
Business Wire (Mon, 9:00AM)
-
at CNBC.com (Fri, 6:02PM)
-
at CNBC.com (May 7, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (Apr 25, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 18, 2013)
-
at CNBC.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 8, 2013)
-
Business Wire (Mar 27, 2013)
-
Business Wire (Feb 27, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 7, 2013)
BAX vs. ETF Alternatives
Company Description
Baxter develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 7, 1:54 PM Barclays comes to the defense of Baxter (BAX -3.1%) this afternoon, upping the stock to Overweight on today's weakness. The stock was hit after the drug-maker said Phase III testing of its Gammagard treatment for Alzheimer's disease did not meet its co-primary endpoints. Comment! [Healthcare, On the Move]
- Tuesday, May 7, 8:25 AM Baxter International (BAX) slips 2.2% premarket after Phase III testing on its Alzheimer's drug immunoglobulin (IG) - always a long shot - failed to meet its co-primary endpoints. (PR) 1 Comment [Healthcare, On the Move]
- Tuesday, May 7, 6:21 AM Baxter International (BAX) declares $0.49/share quarterly dividend, 9% increase from prior dividend of $0.45. Forward yield 2.56%. For shareholders of record June 07. Payable July 01. Ex-div date June 05. (PR) Comment! [Dividends]
- Monday, May 6, 7:02 AM Vical (VICL) says the addition of its Vaxfectin adjuvant to Baxter's (BAX) influenza vaccines "substantially increases both antibody and T-cell responses." VICL's VP of vaccine research says seasonal influenza vaccines sometimes underperform in elderly patients — "a good adjuvant could" help, he adds. (PR) Comment! [Healthcare]
- Friday, April 26, 3:42 PM Looking for dividend picks, Marketwatch screens the S&P 1,500 for 1) Stock trades at less than a 17x PE 2) Dividend yield 20% or more higher than S&P 500 3) Raised dividend at least 5 times in last 5 years 4) S&P Quality Rank of B+ or better. The winners: T, AVA, BAX, CAH, CAG, ED, JNJ, LG, TAP, RAI, SCG, UVV, WR, XEL. 1 Comment
- Thursday, April 18, 9:03 AM More on Baxter (BAX) Q1: net profit -11% to $552M, dragged down by charges related to its purchase of Gambrro, while last year's figures included a tax benefit. Medical-products sales -0.4% to $1.92B, BioScience revenue +4.7% to $1.53B. Expects sales growth of 4% in Q2 and 10% for FY; forecasts EPS of Q2 EPS of $1.12-1.14 vs consensus of $1.14 and 2014 EPS of $4.60-4.70 vs 4.66. (PR) Comment! [Healthcare, Earnings]
- Thursday, April 18, 7:03 AM Baxter (BAX): Q1 EPS of $1.05 in-line. Revenue of $3.45B (+2% Y/Y) misses by $0.04B. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, April 18, 12:05 AM Notable earnings before Thursday’s open: ADS, AN, APH, BAX, BBT, BPOP, BTU, BX, CY, DHR, FCS, FCX, FITB, KEY, LDK, MMR, MS, NOK, NUE, OMC, PBCT, PENN, PEP, PM, PPG, SHW, SNA, SON, TSM, TZOO, UNH, UNP, VZ Comment! [Earnings]
- Wednesday, April 17, 5:30 PM Notable earnings before Thursday’s open: ADS, AN, APH, BAX, BBT, BPOP, BTU, BX, CY, DHR, FCS, FCX, FITB, KEY, LDK, MMR, MS, NOK, NUE, OMC, PBCT, PENN, PEP, PM, PPG, SHW, SNA, SON, TSM, TZOO, UNH, UNP, VZ Comment! [Earnings]
- Thursday, April 4, 4:45 AM The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK). 5 Comments [Healthcare]
- Friday, March 22, 9:29 AM Halozyme Therapeutics (HALO) +18.6% premarket after the European Medicines Agency approves partner Baxter (BAX) for the use of HALO's HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. Upon receiving marketing authorization from the EC, BAX plans to launch HyQvia in some European countries later this year. Comment! [Healthcare, On the Move]
- Tuesday, February 19, 9:35 AM Baxter International Inc. (BAX) declares $0.45/share quarterly dividend, in line with previous. Forward yield 2.64%. For shareholders of record Mar. 08. Payable Apr. 01. Ex-div date Mar. 06. (PR) Comment! [Dividends]
- Thursday, January 24, 9:14 AM More on Baxter's (BAX) Q4 results: Forecasts current-quarter EPS of $1.03-$1.05 on 2%-3% sales growth vs. consensus of $1.10 on 4% revenue growth to $3.5B. Forecasts 2013 EPS of $4.60-$4.70 on 10% sales growth vs. consensus $4.84 on 5% revenue growth of $14.8B. Acquires investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals. Comment! [Earnings, Healthcare]
- Thursday, January 24, 7:03 AM Baxter (BAX): Q4 EPS of $1.26 in-line. Revenue of $3.8B (+4% Y/Y) beats by $0.08B. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, January 24, 12:05 AM Notable earnings before Thursday’s open: ABC, ALK, ARG, AVT, BAX, BMY, BPOP, CELG, CY, DOV, EQT, ESI, ETN, FCS, GWW, JNS, JVA, KCG, KEY, LMT, LUV, MKC, MMM, MWW, NMM, NOK, ORI, PCP, QSII, RTN, RYN, SWK, TZOO, UAL, UNP, XRX Comment! [Earnings]
- Wednesday, January 23, 5:30 PM Notable earnings before Thursday’s open: ABC, ALK, ARG, AVT, BAX, BMY, BPOP, CELG, CY, DOV, EQT, ESI, ETN, FCS, GWW, JNS, JVA, KCG, KEY, LMT, LUV, MKC, MMM, MWW, NMM, NOK, ORI, PCP, QSII, RTN, RYN, SWK, TZOO, UAL, UNP, XRX Comment! [Earnings]
-
WhisperNumber
Alerts issued this morning for $AXP, $BAX, $FITB, $UNP, and $VZ. http://bit.ly/17e4eoA - View all 0 replies
-
WhisperNumber
$BAX earnings $1.05, seven cents short of the whisper number. Expected price reaction: http://seekingalpha.com/a/swgf - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Julius Ferraro
Out of BAX and into HAL. I've never had a better 3 days of trading. Doubled my gains for the year in 3 days :) - View all 0 replies
-
- View all 0 replies
LATEST REPLIES